Scilex Holding Company Operating Lease, Expense
Scilex Holding Company (SCLX) reported Operating Lease, Expense of $1.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-14
- Scilex Holding Company operating lease, expense for the quarter ending 2026-06-30 was $1.10M, a 450.00% increase year-over-year.
- Scilex Holding Company operating lease, expense for the quarter ending 2026-03-31 was $1.20M, a 300.00% increase year-over-year.
- Scilex Holding Company operating lease, expense for the quarter ending 2025-12-31 was $400.00K, a 100.00% increase year-over-year.
- Scilex Holding Company operating lease, expense for the quarter ending 2025-09-30 was $300.00K, a 0.00% change year-over-year.
- Scilex Holding Company operating lease, expense for fiscal 2025 was $1.20M, a 20.00% increase from fiscal 2024.
- Scilex Holding Company operating lease, expense for fiscal 2024 was $1.00M, a 9.09% decline from fiscal 2023.
- Scilex Holding Company operating lease, expense for fiscal 2023 was $1.10M, a 120.00% increase from fiscal 2022.
- Scilex Holding Company operating lease, expense for fiscal 2022 was $500.00K, a 16.67% decline from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-14 | $2.30M 10-Q · filed 2026-08-14 | $2.70M derived: sum of 3 quarters · filed 2026-08-14 | $3.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-20 | $1.60M derived: sum of 2 quarters · filed 2026-05-20 | $1.90M derived: sum of 3 quarters · filed 2026-05-20 | $2.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $700.00K derived: sum of 2 quarters · filed 2026-04-10 | $900.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.20M 10-K · filed 2026-04-10 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-14 | $500.00K derived: sum of 2 quarters · filed 2026-08-14 | $800.00K 10-Q · filed 2025-11-14 | $1.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-14 | $500.00K 10-Q · filed 2026-08-14 | $700.00K derived: sum of 3 quarters · filed 2026-08-14 | $1.00M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $300.00K 10-Q · filed 2026-05-20 | $500.00K derived: sum of 2 quarters · filed 2026-05-20 | $800.00K derived: sum of 3 quarters · filed 2026-05-20 | $1.10M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $500.00K derived: sum of 2 quarters · filed 2026-04-10 | $800.00K derived: sum of 3 quarters · filed 2026-04-10 | $1.00M 10-K · filed 2026-04-10 |
| 2024-09-30 | $300.00K 10-Q · filed 2025-11-14 | $600.00K derived: sum of 2 quarters · filed 2025-11-14 | $800.00K 10-Q · filed 2025-11-14 | $1.20M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $300.00K 10-Q · filed 2025-08-13 | $500.00K 10-Q · filed 2025-08-13 | $900.00K derived: sum of 3 quarters · filed 2025-08-13 | $1.20M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $300.00K 10-Q · filed 2025-05-14 | $600.00K derived: sum of 2 quarters · filed 2025-05-14 | $900.00K derived: sum of 3 quarters · filed 2025-05-14 | $1.20M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $600.00K derived: sum of 2 quarters · filed 2025-03-31 | $900.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.10M 10-K · filed 2025-03-31 |
| 2023-09-30 | $300.00K 10-Q · filed 2025-01-17 | $600.00K derived: sum of 2 quarters · filed 2025-01-17 | $800.00K 10-Q · filed 2025-01-17 | $1.00M derived: sum of 4 quarters · filed 2025-01-17 |
| 2023-06-30 | $300.00K 10-Q · filed 2024-08-13 | $500.00K 10-Q · filed 2024-08-13 | $700.00K derived: sum of 3 quarters · filed 2024-08-13 | $700.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $200.00K 10-Q · filed 2024-05-13 | $400.00K derived: sum of 2 quarters · filed 2024-05-13 | $400.00K derived: sum of 3 quarters · filed 2024-05-13 | $600.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $200.00K derived: sum of 2 quarters · filed 2024-03-12 | $400.00K derived: sum of 3 quarters · filed 2024-03-12 | $500.00K 10-K · filed 2024-03-12 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-14 | $200.00K derived: sum of 2 quarters · filed 2023-11-14 | $300.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $200.00K 10-Q · filed 2023-08-11 | $300.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $600.00K 10-K · filed 2024-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |